|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Biganzoli L et al. Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: Where do we stand? Crit Rev Oncol Hematol 2007;62(1):1-8. Abstract
Dang C et al. Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA). San Antonio Breast Cancer Symposium 2006;Abstract 2101.
Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract
Harries M et al. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer.
J Clin Oncol 2005;23(31):7768-71. No abstract available
Ibrahim NK et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23(25):6019-26. Abstract
Kaufman B et al. Progression-free survival with anastrozole/trastuzumab in postmenopausal women with HER2-positive hormone-dependent metastatic breast cancer. Presentation. Annual Congress of the European Society for Medical Oncology 2006;Abstract LBA2.
Link JS et al. Bevacizumab (Avastin) and albumin bound paclitaxel (Abraxane) treatment in metastatic breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 1095.
Mackey JR et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 3.
Miller K et al. Capecitabine plus bevacizumab in first line metastatic breast cancer: An interim safety and efficacy report of the first phase of Xeloda plus Avastin 1st line metastatic breast cancer trial. San Antonio Breast Cancer Symposium 2006;Abstract 2068.
Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005a;Abstract 3.
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005b;23(4):792-9. Abstract
Morales-Vasquez F et al. Detection of doxorubicin cardiotoxicity in patients with breast cancer by 99mTc-MIBI myocardial perfusion tomography. Proc ASCO 2006;Abstract 10775.
Perik PJ et al. Myocardial HER2 expression with 111In-DTPA-trastuzmab scan in patients shortly after anthracycline treatment. Proc ASCO 2006;Abstract 3057.
Robert N et al. Pilot study of dose dense doxorubicin + cyclophosphamide followed by ABI-007 in patients with early stage breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 2073.
Seidman AD et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc ASCO 2004;Abstract 512.
Traina TA et al. Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). Proc ASCO 2006;Abstract 3050.
Vandenberg TA et al. Pegylated liposomal doxorubicin (PLD) with cyclophosphamide (C) as 1st-line chemotherapy for metastatic breast cancer (MBC) patients previously treated with adjuvant anthracyclines. Proc ASCO 2006;Abstract 10627.
 |
 |
